iCAD Showcases Advanced Mammography and Computed Tomography Colonography (CTC) CAD Solutions at Radiological Society of North America 2014 Annual Meeting
NASHUA, N.H. – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will feature advanced computer-aided detection (CAD) solutions for the early detection of breast and colon cancers during the 100(th) Annual Meeting of the Radiological Society of North America (RSNA), in Chicago, Nov. 30 - Dec. 5. Symposia, posters, and workshops discuss the application of iCAD technologies and workflow solutions for enhanced cancer identification, breast density analysis, and tumor characterization. iCAD's 2D mammography, tomosynthesis, and Computed Tomography Colonography (CTC) CAD and workflow technologies will be featured at booth #4135 in Hall A.
"We are pleased to showcase our latest Cancer Detection technologies at the 100(th) RSNA meeting. Cancer Detection technologies have been proven to help radiologists identify cancer earlier, when there may be more treatment options available," said Ken Ferry, President and CEO of iCAD. "With medical imaging's rapid evolution, iCAD continues to build its CAD offerings to ensure that radiologists have access to the most innovative solutions for optimal patient care."
iCAD will showcase the PowerLook Advanced Mammography Platform (AMP)® and VeraLook® CTC, the first FDA-cleared CAD technology for CTC. PowerLook® has grown to include several modules for breast density assessment, dose assessment and advanced analytics since it was introduced in 2012. iCAD will also be demonstrating a new tomosynthesis workflow tool, as a future product to be released.
The role of volumetric density in adjunctive imaging for women with dense breasts is the topic of numerous poster presentations and workshops. In addition, iCAD's Xoft® cervical brachytherapy for gynecological cancer, MRI imaging for the characterization of pediatric brain tumors and a cloud-based, peer-review platform and workflow solution for large oncology networks will be presented.
Clinical Presentations:
Sunday, November 30
   -- GE Healthcare Workshop: Automated Density Assessment and Screening
       Breast Ultrasound in Clinical PracticeJean Weigert, M.D., 1:30-2:00
       p.m., Booth #4782
Monday, December 1
   -- A Forward Approach for Data Aggregation and Collection to Improve
       Quality of Peer Review Using a Cloud Based Platform within a Large
       Oncology Network (Poster)Dawn Henrich, R.T., director of clinical
       applications of iCAD, 12:45-1:15 p.m. at ROS-MOB, RO Community, Learning
       Center
Tuesday, December 2
   -- Feasibility of Cervical Brachytherapy with a Novel 50 kV Electronic
       Brachytherapy Source J. Spencer Thompson, M.D., 11:40-11:50 a.m. in Room
       S103CD
   -- System-Wide Monitoring of Mammographic Radiation Dose for Quality
       Assurance (Poster)Ralph P Highnam Ph.D., CEO, Matakina Technology
       Limited CEO, Volpara Solutions Limited 12:45-1:15 p.m. at BR Community,
       Learning Center
   -- Fully Automated Volumetric Breast Density Estimation from Digital Breast
       Tomosynthesis Images: Multi-modality Comparison with Digital
       Mammography and Breast MRI (Poster)Said Pertuz Ph.D., 3:20-3:30 p.m. in
       the Arie Crown Theater
Wednesday, December 3
   -- ISP: Gastrointestinal (CT Colonography), 10:30 - 12:00 p.m., SSK08,
       E351Moderated by Andrea Laghi, M.D. and Judy Yee M.D.
       -- Present and Future of CT Colonography, SSK08-01Gastrointestinal
           Keynote Speaker: Abraham H. Dachman, M.D.
Thursday, December 4
   -- Breast Imaging (Breast Density and Risk Assessment)10:30 a.m.-12:00
       p.m., Room E450A
Friday, December 5
   -- Automated processing of dynamic contrast enhanced (DCE) T1 permeability
       perfusion: advanced pharmacokinetic metrics in pediatric brain
       tumorsSridhar Vajapeyam, Ph.D., 11:10 - 11:20 a.m. in Room N229
#MySight: Why we never stop looking
As part of its commitment to the early detection of cancer, iCAD will conduct a social media campaign aimed at supporting the Imerman Angels, a Chicago-based organization that provides one-on-one support to cancer fighters, survivors and caregivers. RSNA attendees can participate by sharing what drives them to "never stop looking" using the hashtag #MySight in social media posts:
   -- Visit iCAD at RSNA in Hall A, booth #4135 and take a picture at iCAD's
       #MySight booth station.
   -- Share the picture on Twitter or Facebook, tag @icadmed and include the
       hashtag #MySight, and tell us why you "never stop looking."
   -- For each Tweet or Facebook post that includes #MySight, iCAD will make a
       donation on your behalf.
Tweets, retweets, mentions, replies, and Facebook posts and shares using the #MySight hashtag during RSNA 2014 (11/30/14 - 12/4/14) are eligible for donation. Posts including the #MySight hashtag from members of the public do not necessarily reflect the views of iCAD and iCAD reserves the right to remove inappropriate, offensive or other material in question at our sole discretion, with or without notice. The #MySight hashtag will not be used for conversations about specific products or treatments. If you have a question about iCAD products, please contact us.
For additional information regarding iCAD and the technologies being discussed at RSNA 2014, please visit http://www.icadmed.com/rsna.html.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while enhancing patient care. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.
Source
iCAD, Inc.
